Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Synthetic Biologics Inc. SYN

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The...


Recent & Breaking News (NYSEAM:SYN)

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

GlobeNewswire September 5, 2022

Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results

GlobeNewswire August 11, 2022

Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022

GlobeNewswire August 4, 2022

Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results

GlobeNewswire August 4, 2022

Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock

GlobeNewswire July 29, 2022

Synthetic Biologics Announces Reverse Stock Split

GlobeNewswire July 15, 2022

Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results

GlobeNewswire May 16, 2022

Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

GlobeNewswire May 10, 2022

Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results

GlobeNewswire May 9, 2022

Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline

GlobeNewswire May 5, 2022

Synthetic Biologics Announces Presentation on VCN-11, a Novel Oncolytic Adenovirus Designed to Evade Neutralizing Antibodies at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

GlobeNewswire May 4, 2022

Synthetic Biologics Announces Journal for ImmunoTherapy of Cancer Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients With Advanced Solid Tumors

GlobeNewswire March 28, 2022

Synthetic Biologics Announces Management Transitions in Support of Strategic Transformation

GlobeNewswire March 23, 2022

Synthetic Biologics to Participate in the Maxim 2022 Virtual Growth Conference

GlobeNewswire March 22, 2022

Synthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results

GlobeNewswire March 16, 2022

Synthetic Biologics Completes Acquisition of VCN Biosciences

GlobeNewswire March 11, 2022

Synthetic Biologics to Host Conference Call and Webcast to Discuss 2021 Year End Operational Highlights and Financial Results

GlobeNewswire March 10, 2022

Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference

PR Newswire February 9, 2022

Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA

PR Newswire February 8, 2022

Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022

PR Newswire January 26, 2022